Literature DB >> 7659199

Isoflurane narcotherapy in depressive patients refractory to conventional antidepressant drug treatment. A double-blind comparison with electroconvulsive treatment.

G Langer1, R Karazman, J Neumark, B Saletu, G Schönbeck, J Grünberger, R Dittrich, W Petricek, P Hoffmann, L Linzmayer.   

Abstract

This is the first report on a controlled study comparing the therapeutic and non-therapeutic (side) effects of electroconvulsive treatment (ECT) and isoflurane narcotherapy (ISONAR; deep anesthesias with the inhalation of anesthetic isoflurane) in drug-refractory, severely depressed women, who had been randomly allocated either to ECT (n = 10) or ISONAR (n = 10). Patients from each group were subjected to a total of six treatment sessions (two sessions per week) and maintained on a fixed antidepressant drug dose. The antidepressant efficacy of either treatment was evaluated for each treatment session (in search of a 'rapid antidepressant effect') and at weekly intervals. Cognitive functions or signs of an organic brain syndrome were evaluated by means of psychological tests and extensive EEG analyses. Rapid antidepressant effects of the first treatment session were only significant in patients on ISONAR; in the subsequent treatment sessions, ECT also induced rapid antidepressant effects. Antidepressant effects during the treatment period were comparable, and patients on ISONAR improved further during follow-up, whereas patients on ECT tended to relapse. ISONAR-treated patients improved in most psychometric variables, whereas patients on ECT deteriorated. Finally, the EEG patterns of the ISONAR-treated patients remained normal or augmented (dominant alpha power), whereas patients on ECT developed an increase in abnormalities in EEG patterns and theta/delta power. This indicates an organic brain syndrome in patients on ECT.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7659199     DOI: 10.1159/000119190

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  10 in total

1.  Effects of electroconvulsive stimuli and MK-801 on neuropeptide Y, neurokinin A, and calcitonin gene-related peptide in rat brain.

Authors:  A A Mathé; S Gruber; P A Jiménez; E Theodorsson; C Stenfors
Journal:  Neurochem Res       Date:  1997-05       Impact factor: 3.996

Review 2.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

3.  GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.

Authors:  Jeffrey Burgdorf; Xiao-lei Zhang; Katherine L Nicholson; Robert L Balster; J David Leander; Patric K Stanton; Amanda L Gross; Roger A Kroes; Joseph R Moskal
Journal:  Neuropsychopharmacology       Date:  2012-12-05       Impact factor: 7.853

4.  Isoflurane produces antidepressant effects inducing BDNF-TrkB signaling in CUMS mice.

Authors:  Sha-Sha Zhang; Yu-Hua Tian; Song-Jun Jin; Wen-Cheng Wang; Jing-Xin Zhao; Xiao-Ming Si; Li Zhang; Hong Xu; Jing-Yu Jin
Journal:  Psychopharmacology (Berl)       Date:  2019-06-13       Impact factor: 4.530

5.  Isoflurane produces antidepressant effects and induces TrkB signaling in rodents.

Authors:  Hanna Antila; Maria Ryazantseva; Dina Popova; Pia Sipilä; Ramon Guirado; Samuel Kohtala; Ipek Yalcin; Jesse Lindholm; Liisa Vesa; Vinicius Sato; Joshua Cordeira; Henri Autio; Mikhail Kislin; Maribel Rios; Sâmia Joca; Plinio Casarotto; Leonard Khiroug; Sari Lauri; Tomi Taira; Eero Castrén; Tomi Rantamäki
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

6.  Propofol for Treatment-Resistant Depression: A Pilot Study.

Authors:  Brian J Mickey; Andrea T White; Anna M Arp; Kolby Leonardi; Marina M Torres; Adam L Larson; David H Odell; Sara A Whittingham; Michael M Beck; Jacob E Jessop; Derek J Sakata; Lowry A Bushnell; Matthew D Pierson; Daniela Solzbacher; E Jeremy Kendrick; Howard R Weeks; Alan R Light; Kathleen C Light; Scott C Tadler
Journal:  Int J Neuropsychopharmacol       Date:  2018-12-01       Impact factor: 5.176

Review 7.  Psychedelics and Other Psychoplastogens for Treating Mental Illness.

Authors:  Maxemiliano V Vargas; Retsina Meyer; Arabo A Avanes; Mark Rus; David E Olson
Journal:  Front Psychiatry       Date:  2021-10-04       Impact factor: 4.157

8.  Antidepressant and neurocognitive effects of isoflurane anesthesia versus electroconvulsive therapy in refractory depression.

Authors:  Howard R Weeks; Scott C Tadler; Kelly W Smith; Eli Iacob; Mikala Saccoman; Andrea T White; Joshua D Landvatter; Gordon J Chelune; Yana Suchy; Elaine Clark; Michael K Cahalan; Lowry Bushnell; Derek Sakata; Alan R Light; Kathleen C Light
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

9.  Leukocyte Gene Expression in Patients with Medication Refractory Depression before and after Treatment with ECT or Isoflurane Anesthesia: A Pilot Study.

Authors:  E Iacob; S C Tadler; K C Light; H R Weeks; K W Smith; A T White; R W Hughen; T A VanHaitsma; L A Bushnell; A R Light
Journal:  Depress Res Treat       Date:  2014-04-13

10.  Isoflurane but Not Halothane Prevents and Reverses Helpless Behavior: A Role for EEG Burst Suppression?

Authors:  P Leon Brown; Panos Zanos; Leiming Wang; Greg I Elmer; Todd D Gould; Paul D Shepard
Journal:  Int J Neuropsychopharmacol       Date:  2018-08-01       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.